|
Synonyms: ASG-22CE | enfortumab vedotin-ejfv | Padcev®
enfortumab vedotin is an approved drug (FDA (2019), EMA (2022))
Compound class:
Antibody
Comment: Enfortumab vedotin is an anti-Nectin 4 monoclonal antibody-drug conjugate [3]. The toxic payload is monomethyl auristatin E (MMAE; PubChem CID 11542188). It exhibits potent efficacy in multiple preclinical cancer models [1].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2019), EMA (2022)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9821 | enfortumab vedotin |
| Synonyms |
| ASG-22CE | enfortumab vedotin-ejfv | Padcev® |
| Database Links |
|
| GtoPdb PubChem SID | 405067331 |
| Search PubMed clinical trials | enfortumab vedotin |
| Search PubMed titles | enfortumab vedotin |
| Search PubMed titles/abstracts | enfortumab vedotin |
